Multiple Myeloma News and Research RSS Feed - Multiple Myeloma News and Research

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.
TUM researchers uncover molecular mechanism of thalidomide

TUM researchers uncover molecular mechanism of thalidomide

In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these disastrous birth defects have remained unclear. [More]
Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry. [More]
PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. [More]
NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. [More]
Carfilzomib therapy shows promise for pre-kidney transplant patients

Carfilzomib therapy shows promise for pre-kidney transplant patients

Early findings by researchers at the University of Cincinnati College of Medicine suggest that the use of a second generation cancer drug, carfilzomib, may provide an improved approach for the reduction of antibodies in potential kidney transplant candidates. [More]
Researchers discover AF1q protein linked to multiple myeloma, EMD

Researchers discover AF1q protein linked to multiple myeloma, EMD

A group of researchers from the University of Louisville, Japan and Austria is the first to identify a protein, AF1q, associated with multiple myeloma and a condition that occurs in approximately one-fourth of very aggressive multiple myeloma, extramedullary disease or EMD. [More]
Scientists discover unexpected functions of snoRNAs that explains cause of some diseases

Scientists discover unexpected functions of snoRNAs that explains cause of some diseases

Scientists have discovered unexpected functions of small nucleolar RNAs (snoRNAs) that explain the cause of some diseases. [More]
Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival. [More]
Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer. [More]
Phase I study of triple drug combination shows promise in multiple myeloma patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. [More]
New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol). [More]
Novel animal model helps understand mechanisms that lead to multiple myeloma

Novel animal model helps understand mechanisms that lead to multiple myeloma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. The study was published in the journal Scientific Reports. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center. [More]
Series of routine tests may not be beneficial to patients with age-related disorder

Series of routine tests may not be beneficial to patients with age-related disorder

A series of tests physicians routinely order to help diagnose and follow their patients with an elevated antibody level that is a marker for cancer risk, often do not benefit the patient but do increase health care costs, pathologists report. [More]
Rab inhibition may be a promising antimyeloma strategy

Rab inhibition may be a promising antimyeloma strategy

Roswell Park Cancer Institute researchers are investigating agents that target and disrupt the trafficking of monoclonal antibodies in multiple myeloma, a cancer of the bone marrow. The results will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans. [More]
PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

Multiple myeloma (MM) is a hematological cancer that frequently acquires resistance to chemotherapeutic drugs. Additionally, many patients experience disease relapse, but these patients are difficult to treat as the cancer is often resistant to the previous treatment regimen. [More]
Radiotherapy needs likely to increase in all European countries by 2025

Radiotherapy needs likely to increase in all European countries by 2025

The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology. [More]
Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists. [More]
Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

Binding Site is proud to be a key collaborator with Prof Sigurdur Kristinsson of the University of Iceland in his pivotal MGUS screening study for the forthcoming iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial. [More]
Advertisement